- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOCON BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 07.05. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 30.04. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 4 | SGX Company Announcements | ||
| 21.04. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 07.04. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 4 | SGX Company Announcements | ||
| 27.03. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 4 | SGX Company Announcements | ||
| 12.02. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 07.02. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 28.01. | S&P Global upgrades Biocon Biologics ratings | 5 | Times of India | ||
| 28.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 15.01. | Biocon Raises Rs 4,150 Crore Via QIP, To Buy Viatris Stake In Biocon Biologics | 20 | The Free Press Journal | ||
| 14.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::ACQUISITION OF BBL SHARES AND ALLOTMENT OF BL EQUITY SHARES | 1 | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::OUTCOME OF BOARD MEETING OF BIOCON LIMITED | 2 | SGX Company Announcements | ||
| 06.12.25 | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | 959 | AFX News | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen | |
| 17.09.25 | Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya and Aukelso, Denosumab Biosimilars | 1.134 | PR Newswire | BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary... ► Artikel lesen | |
| 15.07.25 | Biocon Biologics Ltd: Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States | 220 | GlobeNewswire (Europe) | BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon... ► Artikel lesen | |
| 03.07.25 | Fortschritt für die Knochengesundheit: Europäische Kommission erteilt Zulassung für Denosumab-Biosimilars von Biocon Biologics | 435 | news aktuell | Bengaluru, Indien (ots/PRNewswire) - Biocon Biologics Ltd. (BBL), ein vollständig integriertes globales Biosimilar-Unternehmen und Tochtergesellschaft von Biocon Ltd., gab heute bekannt, dass die Europäische... ► Artikel lesen | |
| 03.07.25 | Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars | 459 | PR Newswire | BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission... ► Artikel lesen | |
| 27.06.25 | Biocon Biologics Ltd: Biocon Biologics Receives Health Canada Approval for Yesafili (aflibercept); First Global Launch Scheduled for July 2025 | 1.004 | GlobeNewswire (Europe) | TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd.... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,64 | +0,06 % | Pharma-Milliardendeal: AbbVie kauft Biotech-Hoffnung - Übernahmeziel schießt um fast 50 % hoch! | © Foto: Nikos Pekiaridis - NurPhotoAbbVie übernimmt Apogee Therapeutics für rund 10,9 Milliarden US-Dollar. Der Deal soll das Immunologiegeschäft stärken und neue Wachstumstreiber schaffen.AbbVie sichert... ► Artikel lesen | |
| QIAGEN | 32,740 | +2,14 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum zweiten Quartal auf "Buy" belassen. Diese dürften sich im Rahmen der eigenen Vorgaben des Diagnostikspezialisten... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,580 | +2,10 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TANGO THERAPEUTICS | 28,755 | +0,89 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,970 | +0,36 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 99,86 | +0,41 % | Truist reiterates Kymera stock Buy rating after AbbVie deal | ||
| BOUNDLESS BIO | 2,305 | +64,64 % | Boundless Bio, Inc.: Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement | Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha's lead program SERP-01 targets the... ► Artikel lesen | |
| BIONTECH | 80,30 | +1,71 % | BioNTech: Fragwürdiger Abgang in Mainz | Eine Abspaltung wirft einige Fragen auf. Ich habe sie dem Unternehmen gestellt. Leider unbefriedigende Antworten. Aus diesem Grund gehe ich jetzt an die Öffentlichkeit. Machen Sie sich gern selbst ein... ► Artikel lesen | |
| BEAM THERAPEUTICS | 36,480 | +2,67 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ERASCA | 15,500 | +2,79 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 304,61 | +0,40 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ABSCI | 7,995 | -4,82 % | Leerink Starts Coverage on Absci Corporation (ABSI) | ||
| MODERNA | 55,68 | +7,18 % | Moderna: +10 Prozent - FDA-Termin zündet die Aktie | Die Moderna-Aktie legt am Dienstag kräftig zu. Mit einem Plus von rund zehn Prozent ist sie einer der Top-Gewinner im US-Handel. Auslöser ist eine Kombination aus regulatorischen Neuigkeiten und einem... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,80 | +1,95 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| ALUMIS | 24,920 | +1,30 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen |
BIOCON BIOLOGICS GLOBAL PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,13 (-0,13 %) liegt der Kurs bei 100,18 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCON BIOLOGICS GLOBAL PLC finden Sie auf Wallstreet Online.